Zealand Pharma AS (WBO:ZEAL) Cyclically Adjusted PB Ratio: (As of Aug. 10, 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

WBO:ZEAL Zealand Pharma AS WBO:ZEAL
45 GF Score
Price €43.48
GF Value €1,549.05
Valuation Possible Value Trap
! 3 Warning Signs
View Full Analysis

What is Zealand Pharma AS Cyclically Adjusted PB Ratio?

Note: If the price history is too short, we do not calculate current Cyclically Adjusted PB Ratio for this stock. All the historical data is shown as the company's primary share's data instead.

Shiller PE for Stocks: The True Measure of Stock Valuation


Zealand Pharma AS  (WBO:ZEAL) Cyclically Adjusted PB Ratio Explanation

Compared with the regular PB Ratio, which works poorly for cyclical businesses, the Cyclically Adjusted PB Ratio smoothed out the fluctuations of book value during business cycles. Therefore it is more accurate in reflecting the valuation of the company.

If a company has consistent business performance, the Cyclically Adjusted PB Ratio should give similar results to regular PB Ratio.


Zealand Pharma AS Cyclically Adjusted PB Ratio Related Terms


Zealand Pharma AS Cyclically Adjusted PB Ratio Historical Data

* Premium members only.

The historical data trend for Zealand Pharma AS's Cyclically Adjusted PB Ratio can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Zealand Pharma AS Cyclically Adjusted PB Ratio Chart

Zealand Pharma AS Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Cyclically Adjusted PB Ratio
Get a 7-Day Free Trial Premium Member Only Premium Member Only 6.62 8.96 16.10 21.90 9.07

Zealand Pharma AS Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Cyclically Adjusted PB Ratio Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 14.49 8.62 9.88 9.07 5.22

WBO:ZEAL vs VRTX, REGN, RVMD: Cyclically Adjusted PB Ratio Comparison

For the Biotechnology subindustry, Zealand Pharma AS's Cyclically Adjusted PB Ratio, along with its competitors' market caps and Cyclically Adjusted PB Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Zealand Pharma AS Cyclically Adjusted PB Ratio vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Zealand Pharma AS's Cyclically Adjusted PB Ratio distribution charts can be found below:

* The bar in red indicates where Zealand Pharma AS's Cyclically Adjusted PB Ratio falls into.


WBO:ZEAL
45GF Score
Zealand Pharma AS WBO:ZEAL
Cyclically Adjusted PB Ratio is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Zealand Pharma AS Cyclically Adjusted PB Ratio Calculation

Like the Shiller PE Ratio, the Cyclically Adjusted PB Ratio takes the Book Value per Share from the past 10 years, adjusts it for inflation, and then calculates the average. This average is then used for the P/B calculation. Because it considers this 10-year average, it's often referred to as the CAPB Ratio.

The Shiller PE Ratio was first used by professor Robert Shiller to measure the valuation of the overall market. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted PB Ratio.

Zealand Pharma AS's Cyclically Adjusted Book per Share for the quarter that ended in Mar. 2026 is calculated as:

For example, Zealand Pharma AS's adjusted Book Value per Share data for the three months ended in Mar. 2026 was:

Adj_Book=Book Value per Share/CPI of Mar. 2026 (Change)*Current CPI (Mar. 2026)
=27.396/121.6800*121.6800
=27.396

Current CPI (Mar. 2026) = 121.6800.

Zealand Pharma AS Quarterly Data

Book Value per Share CPI Adj_Book
201606 0.603 100.600 0.729
201609 1.145 100.200 1.390
201612 1.462 100.300 1.774
201703 1.328 101.200 1.597
201706 0.952 101.200 1.145
201709 2.797 101.800 3.343
201712 2.254 101.300 2.707
201803 1.912 101.700 2.288
201806 1.383 102.300 1.645
201809 5.418 102.400 6.438
201812 4.870 102.100 5.804
201903 4.597 102.900 5.436
201906 4.075 102.900 4.819
201909 5.273 102.900 6.235
201912 4.440 102.900 5.250
202003 4.408 103.300 5.192
202006 6.075 103.200 7.163
202009 5.383 103.500 6.329
202012 4.152 103.400 4.886
202103 5.179 104.300 6.042
202106 4.282 105.000 4.962
202109 3.694 105.800 4.248
202112 2.887 106.600 3.295
202203 2.208 109.900 2.445
202206 1.471 113.600 1.576
202209 1.063 116.400 1.111
202212 2.131 115.900 2.237
202303 1.747 117.300 1.812
202306 3.982 116.400 4.163
202309 4.179 117.400 4.331
202312 3.661 116.700 3.817
202403 6.110 118.400 6.279
202406 17.751 118.500 18.227
202409 16.864 118.900 17.258
202412 16.354 118.900 16.736
202503 15.757 120.200 15.951
202506 29.727 120.700 29.968
202509 28.903 121.600 28.922
202512 28.123 121.200 28.234
202603 27.396 121.680 27.396

Add all the adjusted book value per share together and divide the count will get our Cyclically Adjusted Book per Share.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.

Is Zealand Pharma AS (WBO:ZEAL) Overvalued in 2026?

Based on GuruFocus' analysis, Zealand Pharma AS stock appears to be undervalued. The current stock price of €43.48 is trading 97.2% below its estimated GF Value™ of €1,549.05. GuruFocus considers Zealand Pharma AS to be Possible Value Trap.

Key valuation signals for WBO:ZEAL:

  • Cyclically Adjusted PB Ratio:
  • GF Value™: €1,549.05 vs. price of €43.48 (97.2% below fair value)
  • GF Score™: 45/100 with 3 warning signs

No single metric tells the full story. See the WBO:ZEAL stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.


Zealand Pharma AS Business Description

Address Sydmarken 11, Soborg, DNK, DK-2860
Zealand Pharma AS is a biotechnology company. It is focused on the discovery, design, and development of peptide-based medicines. The company's product pipeline includes three product candidates in clinical development: glepaglutide, which is being developed to treat short bowel syndrome or SBS; dasiglucagon formulated for use in a dual-hormone artificial pancreas system for diabetes management; and dasiglucagon for use in the treatment of congenital hyperinsulinism. The company has out-licensed a peptide program to Boehringer Ingelheim that has been moved ahead into early clinical development: a once-weekly novel dual-acting GLP-1/glucagon agonist for the treatment of obesity and/or Type 2 diabetes.
45GF Score

Get the complete analysis for WBO:ZEAL

Cyclically Adjusted PB Ratio is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€43.48
Price
€1,549.05
GF Value